Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome

Catheterization and Cardiovascular Interventions

Volumn 62, Issue 2, 2004, Pages 193-197

  Chang, Su Min ^a   Yazbek, Naji ^a   Lakkis, Nasser M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Clinical outcome; Myonecrosis; Percutaneous coronary intervention; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; MEVINOLIN; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR EVENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; NONFATAL HEART INFARCTION; OUTCOMES RESEARCH; PROSPECTIVE STUDY; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY DISEASE; CREATINE KINASE; CREATINE KINASE, MB FORM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SYNDROME; TREATMENT OUTCOME;

EID: 2942720651     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20078     Document Type: Article

References (27)

1. Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: west of Scotland coronary prevention study group. N Engl J Med 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-1009.
4. Post Coronary Artery Bypass Graft Trial investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
5. Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
6. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study - a randomized controlled trial. JAMA 2001;285:1711-1718.
7. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-696.
8. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-q-wave myocardial infarction. Circulation 2002;106:2180.
9. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-251.
10. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101:570-580.
11. Aronow HD, McRae T, Quinn MJ, et al. Patients on lipid-lowering therapy at the time of myocardial infarction have smaller infarcts: further evidence to suggest a salutary effect in acute coronary syndrome. J Am Coll Cardiol 2002;39:318A.
12. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-436.
13. Ellis SG, Chew DP, Chan AW, et al. Death following creatine kinase-MB elevation after coronary intervention identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205.
14. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting: randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/ IIIa blockade. Lancet 1998;352:87-89.
15. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-1719.
16. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-1678.
17. Jones SP, Lefer DJ. Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. Acta Physiol Scand 2001;173:139-143.
18. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-251.
19. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000;153:181-189.
20. Plenge JK. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106:1447-1452.
21. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. J Am Coll Cardiol 2003;41(Suppl A):84A.
22. Walter DH, Fichtlscherer S, Britten MB, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001;38:2006-2012.
23. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE) - a randomized trial and cohort study. JAMA 2001;286:64-70.
24. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
25. Serruys PW, De Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-3222.
26. Walter DH, Schasinger V, Elsner M, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-968.
27. Walter DH, Schasinger V, Elsner M, et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the P1(A2)allele of the platelet glycoprotein IIIa gene. Eur Heart J 2001;22:587-595.